Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/cod.13385 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A Real-World Disproportionality Analysis of Histamine H2-Receptors Antagonists (Famotidine): A Pharmacovigilance Study Based on Spontaneous Reports in the FDA Adverse Event Reporting System.
Drug Dev Res
February 2025
Department of Gastroenterology, Zhongshan Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China.
Famotidine is an H2 receptor antagonist and is currently used on a large scale in gastroenterology. However, Famotidine may also cause severe toxicity to organ systems, including the blood system, digestive system, and urinary system. The objective of this study was to scientifically and systematically investigate the adverse events (AEs) of Famotidine in the real world through the FDA Adverse Event Reporting System (FAERS) database.
View Article and Find Full Text PDFVaginal Transcriptional Signatures of the Neutrophil-Driven Immune Response Correlate With Clinical Severity During Recurrent Vulvovaginal Candidiasis.
Am J Reprod Immunol
January 2025
Department of Medicine Solna, Division of Infectious Diseases, Karolinska Institutet, Department of Infectious Diseases, Karolinska University Hospital, Center for Molecular Medicine, Stockholm, Sweden.
Problem: Recurrent vulvovaginal candidiasis (RVVC) affects 5%-10% of all women, negatively impacting their reproductive health and quality of life. Herein, we investigated the molecular effects of RVVC on the vaginal mucosa of otherwise healthy women.
Method Of Study: Gene expression analysis was performed on vaginal tissue biopsies from women with RVVC, including those with a current episode of vulvovaginal candidiasis (VVC, n = 19) and women between infections (culture negative RVVC [CNR], n = 8); women asymptomatically colonized with Candida albicans (asymptomatic [AS], n = 7); and healthy controls (n = 18).
Review of current and emerging estrogen receptor agonists for vaginal atrophy.
Expert Opin Pharmacother
January 2025
Femicare vzw, Tienen, Belgium.
Introduction: Vulvovaginal atrophy (VVA) predominantly affects postmenopausal women due to hormonal decline but can also occur in premenopausal women with conditions such as primary ovarian insufficiency or exposure to anti-estrogen medications. Contributing factors include smoking and certain medical treatments. Symptoms like dyspareunia and loss of sexual function affect many women but are underreported due to stigma and lack of awareness.
View Article and Find Full Text PDFRefractory Vulvovaginal Lichen Planus Responding to Oral Tofacitinib.
Australas J Dermatol
December 2024
Department of Pathology and Lab Medicine, All India Institute of Medical Sciences, Jodhpur, India.
Erosive vulvovaginal lichen planus is a severe form of Lichen planus (LP) that can result in chronic scarring if not treated. It can cause narrowing of the introitus, resulting in pain, itch, dyspareunia, dysuria, and recurrent urinary tract infections caused by retention of urine. Therefore, an effective and safer therapeutic approach is required.
View Article and Find Full Text PDFAnxiety and Depression in Japanese Patients with Genitourinary Syndrome of Menopause.
Int Urogynecol J
December 2024
Department of Obstetrics and Gynecology, Tokyo Dental College Ichikawa General Hospital, Ichikawa, Chiba, Japan.
Introduction And Hypothesis: Women with genitourinary syndrome of menopause (GSM) may have anxiety and depression; however, this is unclear.
Methods: A total of 646 postmenopausal women undergoing treatment for menopausal symptoms were enrolled in this retrospective cross-sectional study. Questionnaire responses were recorded at the first visit, and participants were divided into GSM (≥1 moderate or severe GSM symptom) or no-GSM (without any moderate/severe symptoms) groups.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!